Guidance Offers IDE Tips For Devices Targeting Brain Disease Progression
This article was originally published in The Gray Sheet
FDA issued a draft guidance to help device-makers conduct clinical trials for products designed to slow the progress of neurological conditions. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.
You may also be interested in...
The US agency finalized its guidance on IDEs for devices intended to treat the cause or progression, rather than just the symptoms, of neurological conditions like Alzheimer's.
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first